Centrally acting antihypertensive drugs. Present and future

Clinical and Experimental Hypertension

Volumn 21, Issue 5-6, 1999, Pages 859-873

  Van Zwieten, P A ^a  

^a UNIVERSITY OF AMSTERDAM   (Netherlands)

Author keywords

Centrally acting antihypertensives; Imidazoline receptors; Moxonidine; Rilmenidine

Indexed keywords

ALPHA 2 ADRENERGIC RECEPTOR; ANTIHYPERTENSIVE AGENT; CLONIDINE; GUANABENZ; GUANFACINE; IMIDAZOLINE RECEPTOR; METHYLDOPA; MOXONIDINE; RILMENIDINE; URAPIDIL;

ALPHA ADRENERGIC STIMULATION; ANTIHYPERTENSIVE ACTIVITY; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DROWSINESS; DRUG EFFICACY; DRUG MECHANISM; DRUG RECEPTOR BINDING; FATIGUE; HUMAN; HYPERTENSION; IMPOTENCE; METABOLIC DISORDER; ORAL DRUG ADMINISTRATION; XEROSTOMIA;

EID: 0032802705     PISSN: 10641963     EISSN: None     Source Type: Journal    
DOI: 10.3109/10641969909061015     Document Type: Conference Paper

References (29)

1. Van Zwieten PA, Thoolen MJMC, Timmermans PBMWM. The hypotensive activity and side-effects of methyldopa, clonidine and guanfacine. Hypertension 1984; 6 (suppl.11): 28-33.
2. Van Zwieten PA, Thoolen MJMC, Timmermans PBMWM. The pharmacological base of the hypotensive activity and side-effects of α-methyl-DOPA, clonidine and guanfacine. Hypertension 1984; 6: 11-28.
3. Van Zwieten PA, Chalmers JP. Different types of centrally acting antihypertensives and their targets in the central nervous system. Cardiovasc.Drugs Ther, 1994; 8: 787-799.
4. Van Zwieten PA. Different types of centrally acting anti-hypertensive drugs. Eur.Heart J. 1989; 3: 121-133.
5. 2-adrenoceptor agonists with a central action. Am.J.Cardiol. 1986; 57: 3E-5E.
6. Prichard BNC, Tomlinson B, Renondin JC. Urapidil, a multiple action α-blocking drug. Am.J.Cardiol. 1989; 64: 11D-15D.
7. Van Zwieten PA, Blauw GJ, van Brummelen P. Serotonergic receptors and drugs in hypertension. Pharmacol. Toxicol. 1992; 70 (suppl.II): S17-S22.
8. Michel MC, Ernsberger P. Keeping an eye on the I-site: imidazoline-preferring receptors. Trends Pharmacol. Sci. 1992; 13: 369-370.
9. Hieble JP, Ruffolo RR. Imidazoline receptors: historical perspective. Fundam.Clin.Pharmacol. 1992; 6 (suppl.1): 7S-13S.
10. 1-imidazoline receptor agonist moxonidine: a new antihypertensive. 2nd Edition. Roy.Soc.Med.Press London 1996; pp. 31-47.
11. United Kingdom Working Party on rilmenidine. Rilmenidine in mild-to-moderate essential hypertension. Curr.Ther.Res. 1990; 1: 194-211.
12. Pilastre JP, Letac B, Galinier F, Le Bihan G, Schwartz J. A multicenter double-blind comparative study of rilmenidine and clonidine in 333 hypertensive patients. Am.J.Cardiol. 1988; 61: 81D-85D.
13. Mitrovic V, Patyna W, Hüting J, Schlepper W. Haemodynamic and neurohormonal effects of moxonidine in patients with essential hypertension. Cardiovasc.Drugs Ther. 1991; 5: 967-972.
14. 1-imidazoline receptor agonist moxonidine: a new antihypertensive. 2nd Edition. Roy.Soc.Med.Press London 1996;pp.49-77.
15. Eichstädt H, Richter W, Bäder M. Demonstration of hypertrophy regression with magnetic resonance tomography under the new adrenergic inhibitor moxonidine. Cardiovasc.Drugs Ther. 1989; 3 (suppl.2): 583-587.
16. N'Guyen Van Cao S, Levy B, Slama R. Non-invasive study of cardiac structure and function after rilmenidine for essential hypertension. Am. J. Cardiol. 1988; 61: 72D-75D.
17. Frei M, Küster L, Gardosch von Krosigk PP. Moxonidine and hydrochlorothiazide in combination: a synergistic antihyper-tensive effect. J.Cardiovasc.Pharmacol. 1994; 24 (suppl.1): S25-S28.
18. Fiorentini C, Guillet C, Guazzi M. A multicentre double-blind trial comparing rilmenidine 1 mg and hydrochlorothiazide in 244 patients. Arch.Mal.Coeur Vaiss. 1989; 82: 39-46.
19. Panfilov V, Morris AD, Donelly R, Reid JL. Comparative effects ot rilmenidine and atenolol on tests of autonomie function and mental and dynamic exercise in patients with essential hypertension. J.Cardiovasc.Pharmacol. 1995; 26 (suppl.2): S44-S47.
20. Morrison PJ, Corcoran C, Vivet P. Effect of rilmenidine on alertness. JAMA (French ed.) 1990; special issue, July: 27-28.
21. Thoolen MJMC, Timmermans PBMWM, van Zwieten PA. Withdrawal phenomena of some centrally acting antihypertensieve drugs in the rat. Brit.J.Clin.Pharmacol. 1983; 15: 491S-505S.
22. Crisp P, Faulds A. Moxonidine. Drugs 1992; 44: 993-1012.
23. Rupp H, Maisch B, Brilla C. Drug withdrawal and rebound hypertension. Differential action of the central antihypertensieve drugs moxonidine and clonidine. Cardiovasc.Drugs Ther. 1996; 10 (suppl.1): 251-262.
24. Kaan EC, Brückner R, Frohly P, Tulp M, Scharer SG, Ziegler D. Effects of agmatine and moxonidine on glucose metabolism. Cardiovasc.Risk Fact. 1995; 5 (suppl.1): 19-27.
25. Krentz AJ, Evans AJ. Selective imidazoline receptor agonists for metabolic syndrome. Lancet 1998; 351: 152-154.
26. Ernsberger P, Koletsky RJ, Collinds LA, Bedol B. Sympathetic nervous system in salt-sensitive and obese hypertension: amelioration of multiple abnormalities by a central sympatholytic agent. Cardiovasc.Drugs Ther. 1996; 10: 275-282.
27. Rosen P, Ohly P, Gleichman H. Experimental benefit of moxonidine on glucose metabolism and insulin secretion in the fructose-fed rat. J.Hypertens. 1997; 15 (suppl.1): S31-S38.
28. Manolis AJ, Olympics C, Sifaki M. Suppressing sympathetic activation in congestive heart failure. A new therapeutic strategy. Hypertension 1995; 26: 719-724.
29. Julius S. Sympathetic overactivity and the pathophysiology of coronary risk in hypertension. Cardiovasc.Risk Fact. 1995; 5 (suppl.1): 2-10.